- CORRECTING and REPLACING PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical
- Analyses Find Patients With Polycythemia Vera (PV) Treated With BESREMi® (ropeginterferon alfa-2b) Had Increased Probability of Achieving Complete Hematologic Response
- PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) Now Recommended as a Preferred First-line Cytoreductive Therapy for Polycythemia Vera in Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
- Clinical Review of Pegylated Interferons Suggests Formulation and Mechanism of Action May Improve Outcomes for MPN Patients
Key statistics
On Friday, PharmaEssentia Corp (6446:TAI) closed at 312.50, 14.05% above the 52 week low of 274.00 set on Aug 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 311.50 |
---|---|
High | 315.00 |
Low | 308.00 |
Bid | 312.00 |
Offer | 312.50 |
Previous close | 310.50 |
Average volume | 1.18m |
---|---|
Shares outstanding | 340.81m |
Free float | 262.12m |
P/E (TTM) | -- |
Market cap | 105.82bn TWD |
EPS (TTM) | -2.05 TWD |
Data delayed at least 20 minutes, as of May 10 2024.
More ▼